Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: An open-label pilot study

Autores
Coelho, Claudia; Figueiredo, Ricardo; Frank, Elmar; Burger, Julia; Schecklmann, Martin; Landgrebe, Michael; Langguth, Berthold; Elgoyhen, Ana Belen
Año de publicación
2012
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Tinnitus, the phantom perception of sounds, is a highly prevalent disorder. Although a wide variety of drugs have been investigated off label for the treatment of tinnitus, there is no approved pharmacotherapy. We report an open-label exploratory pilot study to assess the effect of muscle relaxants acting on the central nervous system on tinnitus patients. Cyclobenzaprine at high (30 mg) and low doses (10 mg), orphenadrine (100 mg), tizanidine (24 mg) and eperisone (50 mg) were administered to a maximum of 20 patients per group over a 12-week period. High-dose cyclobenzaprine resulted in a significant reduction in the Tinnitus Handicap Inventory (THI) score between baseline and week 12 in the intention-to-treat sample. On the other hand, other treatments were not effective. These results were confirmed in an explorative analysis where baseline corrected THI and Clinical Global Impression scores at week 12 were compared between groups. The present open trial presents a new promising pharmacotherapy for tinnitus that should be validated in placebo-controlled double-blind trials.
Fil: Coelho, Claudia. University of Iowa; Estados Unidos. Universidade Federal do Rio Grande do Sul; Brasil
Fil: Figueiredo, Ricardo. Clinical and Research Tinnitus Center; Brasil
Fil: Frank, Elmar. Universitat Regensburg; Alemania
Fil: Burger, Julia. Universitat Regensburg; Alemania
Fil: Schecklmann, Martin. Universitat Regensburg; Alemania
Fil: Landgrebe, Michael. Universitat Regensburg; Alemania
Fil: Langguth, Berthold. Universitat Regensburg; Alemania
Fil: Elgoyhen, Ana Belen. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina
Materia
Muscle Relaxants
Phantom Perception
Somatosensory System
Tinnitus
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/79403

id CONICETDig_e43ca25251c9a76cb458eda443e386a4
oai_identifier_str oai:ri.conicet.gov.ar:11336/79403
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: An open-label pilot studyCoelho, ClaudiaFigueiredo, RicardoFrank, ElmarBurger, JuliaSchecklmann, MartinLandgrebe, MichaelLangguth, BertholdElgoyhen, Ana BelenMuscle RelaxantsPhantom PerceptionSomatosensory SystemTinnitushttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Tinnitus, the phantom perception of sounds, is a highly prevalent disorder. Although a wide variety of drugs have been investigated off label for the treatment of tinnitus, there is no approved pharmacotherapy. We report an open-label exploratory pilot study to assess the effect of muscle relaxants acting on the central nervous system on tinnitus patients. Cyclobenzaprine at high (30 mg) and low doses (10 mg), orphenadrine (100 mg), tizanidine (24 mg) and eperisone (50 mg) were administered to a maximum of 20 patients per group over a 12-week period. High-dose cyclobenzaprine resulted in a significant reduction in the Tinnitus Handicap Inventory (THI) score between baseline and week 12 in the intention-to-treat sample. On the other hand, other treatments were not effective. These results were confirmed in an explorative analysis where baseline corrected THI and Clinical Global Impression scores at week 12 were compared between groups. The present open trial presents a new promising pharmacotherapy for tinnitus that should be validated in placebo-controlled double-blind trials.Fil: Coelho, Claudia. University of Iowa; Estados Unidos. Universidade Federal do Rio Grande do Sul; BrasilFil: Figueiredo, Ricardo. Clinical and Research Tinnitus Center; BrasilFil: Frank, Elmar. Universitat Regensburg; AlemaniaFil: Burger, Julia. Universitat Regensburg; AlemaniaFil: Schecklmann, Martin. Universitat Regensburg; AlemaniaFil: Landgrebe, Michael. Universitat Regensburg; AlemaniaFil: Langguth, Berthold. Universitat Regensburg; AlemaniaFil: Elgoyhen, Ana Belen. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; ArgentinaKarger2012-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/79403Coelho, Claudia; Figueiredo, Ricardo; Frank, Elmar; Burger, Julia; Schecklmann, Martin; et al.; Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: An open-label pilot study; Karger; Audiology And Neuro-otology; 17; 3; 4-2012; 179-1881420-3030CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1159/000335657info:eu-repo/semantics/altIdentifier/url/https://www.karger.com/Article/Abstract/335657info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:56:40Zoai:ri.conicet.gov.ar:11336/79403instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:56:40.773CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: An open-label pilot study
title Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: An open-label pilot study
spellingShingle Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: An open-label pilot study
Coelho, Claudia
Muscle Relaxants
Phantom Perception
Somatosensory System
Tinnitus
title_short Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: An open-label pilot study
title_full Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: An open-label pilot study
title_fullStr Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: An open-label pilot study
title_full_unstemmed Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: An open-label pilot study
title_sort Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: An open-label pilot study
dc.creator.none.fl_str_mv Coelho, Claudia
Figueiredo, Ricardo
Frank, Elmar
Burger, Julia
Schecklmann, Martin
Landgrebe, Michael
Langguth, Berthold
Elgoyhen, Ana Belen
author Coelho, Claudia
author_facet Coelho, Claudia
Figueiredo, Ricardo
Frank, Elmar
Burger, Julia
Schecklmann, Martin
Landgrebe, Michael
Langguth, Berthold
Elgoyhen, Ana Belen
author_role author
author2 Figueiredo, Ricardo
Frank, Elmar
Burger, Julia
Schecklmann, Martin
Landgrebe, Michael
Langguth, Berthold
Elgoyhen, Ana Belen
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Muscle Relaxants
Phantom Perception
Somatosensory System
Tinnitus
topic Muscle Relaxants
Phantom Perception
Somatosensory System
Tinnitus
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Tinnitus, the phantom perception of sounds, is a highly prevalent disorder. Although a wide variety of drugs have been investigated off label for the treatment of tinnitus, there is no approved pharmacotherapy. We report an open-label exploratory pilot study to assess the effect of muscle relaxants acting on the central nervous system on tinnitus patients. Cyclobenzaprine at high (30 mg) and low doses (10 mg), orphenadrine (100 mg), tizanidine (24 mg) and eperisone (50 mg) were administered to a maximum of 20 patients per group over a 12-week period. High-dose cyclobenzaprine resulted in a significant reduction in the Tinnitus Handicap Inventory (THI) score between baseline and week 12 in the intention-to-treat sample. On the other hand, other treatments were not effective. These results were confirmed in an explorative analysis where baseline corrected THI and Clinical Global Impression scores at week 12 were compared between groups. The present open trial presents a new promising pharmacotherapy for tinnitus that should be validated in placebo-controlled double-blind trials.
Fil: Coelho, Claudia. University of Iowa; Estados Unidos. Universidade Federal do Rio Grande do Sul; Brasil
Fil: Figueiredo, Ricardo. Clinical and Research Tinnitus Center; Brasil
Fil: Frank, Elmar. Universitat Regensburg; Alemania
Fil: Burger, Julia. Universitat Regensburg; Alemania
Fil: Schecklmann, Martin. Universitat Regensburg; Alemania
Fil: Landgrebe, Michael. Universitat Regensburg; Alemania
Fil: Langguth, Berthold. Universitat Regensburg; Alemania
Fil: Elgoyhen, Ana Belen. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina
description Tinnitus, the phantom perception of sounds, is a highly prevalent disorder. Although a wide variety of drugs have been investigated off label for the treatment of tinnitus, there is no approved pharmacotherapy. We report an open-label exploratory pilot study to assess the effect of muscle relaxants acting on the central nervous system on tinnitus patients. Cyclobenzaprine at high (30 mg) and low doses (10 mg), orphenadrine (100 mg), tizanidine (24 mg) and eperisone (50 mg) were administered to a maximum of 20 patients per group over a 12-week period. High-dose cyclobenzaprine resulted in a significant reduction in the Tinnitus Handicap Inventory (THI) score between baseline and week 12 in the intention-to-treat sample. On the other hand, other treatments were not effective. These results were confirmed in an explorative analysis where baseline corrected THI and Clinical Global Impression scores at week 12 were compared between groups. The present open trial presents a new promising pharmacotherapy for tinnitus that should be validated in placebo-controlled double-blind trials.
publishDate 2012
dc.date.none.fl_str_mv 2012-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/79403
Coelho, Claudia; Figueiredo, Ricardo; Frank, Elmar; Burger, Julia; Schecklmann, Martin; et al.; Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: An open-label pilot study; Karger; Audiology And Neuro-otology; 17; 3; 4-2012; 179-188
1420-3030
CONICET Digital
CONICET
url http://hdl.handle.net/11336/79403
identifier_str_mv Coelho, Claudia; Figueiredo, Ricardo; Frank, Elmar; Burger, Julia; Schecklmann, Martin; et al.; Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: An open-label pilot study; Karger; Audiology And Neuro-otology; 17; 3; 4-2012; 179-188
1420-3030
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1159/000335657
info:eu-repo/semantics/altIdentifier/url/https://www.karger.com/Article/Abstract/335657
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Karger
publisher.none.fl_str_mv Karger
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613700681465856
score 13.070432